News
It's time to outlaw sunburn on reality TV shows - enough is enough
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Introducing SunSense Sunscreen
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.
60 Minutes' MIA Patient Feature Program
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
New practice-changing research will reduce the need for major surgery in many melanoma patients
New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.
Australian researchers pioneer life-extending treatment for advanced melanoma patients with brain tumours
Australian researchers are the first to demonstrate that patients with advanced melanoma which has spread to the brain can have increased life expectancy and possibly even beat the disease.
Melanoma March 2017 wraps up!
Melanoma March 2017 - that's a wrap! Thank you to everyone that helped make it happen.
Melanoma March 2017 helping kick start the Big Data for Melanoma national Research Project!
Thank you so much to all those who contributed in a variety of ways to Melanoma March 2017 in 17 different locations and more around the country! You have contributed to getting the Big Data for Melanoma national Research Project happening!
Shining a light on melanomas that aren't caused by the sun
‘Slip, slop, slap’ is synonymous with being Australian and playing it safe in the sun. These sun smart rules reduce our chances of getting melanoma of the skin. However, new research tells a different story for those affected by rarer forms of melanoma.
Celebrating 60 Years of melanoma research to save lives
MIA is proud to be celebrating an important milestone – the 60th anniversary of melanoma research and Australian-led global efforts to find a cure.
Celebrating our research achievements
Research achievements by MIA were celebrated at the annual Sydney Medical School recently.
Melanoma Information Forum
We
Promising data for advanced melanoma patients
MIA has presented promising data regarding progression-free survival rates for advanced melanoma patients at the ESMO 2019 Congress in Barcelona.
Melanoma Information Forum
We
Community Fundraising September Wrap-Up
Another month has flown by and yet again we have a host of amazing community fundraisers who generously gave up their time to help us reach our goal of zero deaths from melanoma.
Notice for Supporters to Submit to PBAC
Comments in favour of giving patients with BRAF-positive melanoma access to first-line immunotherapy need to be submitted online prior to October 9, 2019.
Tune into Jay's Longest Melanoma March Channel 10 documentary
Jay's Longest Melanoma March documentary is screening this Sunday 22 September at 1pm (AEST) on Channel 10, capturing behind the scenes of the 2000km walk, Adelaide to Sydney in 50 days. Uniting to end melanoma.
Professor Georgina Long Co -Medical Director named Women of Influence in AFR Top 100 List
We are proud to announce that our Professor Georgina
Community Fundraising August Wrap-Up
It’s been a month since we highlighted some of our incredibly generous community fundraisers. We thought we’d have a look back at August and put the spotlight on more of the wonderful people who give up their time to fundraise for MIA, so we can continue to edge closer to our goal of zero deaths from melanoma.
From Lab Coats To Lycra - Australian Melanoma experts take on world Triathlon championships
They are a formidable team - in work and in play
Melanoma Institute Australia hosts SunSafe Student Ambassador Programs 2019
This week, Melanoma Institute Australia hosted the first of six
Australia at risk of falling behind USA and Europe in preventing deadly recurrence of Melanoma
Federal government urged
Team Melanoma smashes City2Surf
We want to thank every member of Team Melanoma and everyone who donated to them. With your help, we are moving closer to our goal of zero deaths from melanoma!
Ready to run over melanoma at City2Surf 2019
Lauren O'Brien tells us why she's running for a cause close to her heart
Community Fundraising July Wrap-Up
MIA could not do what we do without the incredible support and effort of our community fundraisers. We’d like to highlight some of the wonderful events organised by our community in
Breast cancer drug may hold key to tackling most deadly type of melanoma
An international study, led by researchers from Melanoma Institute Australia, QIMR Berghofer Medical Research Institute and The University of Sydney as part of the Australian Melanoma Genome Project, has discovered that a drug traditionally used to treat a
MIA takes centre stage at leading cancer conference
Researchers from Melanoma Institute Australia took centre stage at the American Society of Clinical Oncology Annual Meeting in Chicago. Results presented by MIA’s contingent have the potential to create better patient outcomes and change the way advanced melanoma
International Clinical Trials Day 2019
Today is International Clinical Trials Day – a day to recognise and thank the amazing people who conduct, organise, and coordinate clinical trials.
Emma Betts' legacy will live on
“I’m the age Emma was when she passed away. It almost feels
Support PBS listing for three adjuvant treatments of resected Stage III melanoma
As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions
Support PBS listing for pembrolizumab
As always, part of the PBAC process invites clinicians, patients and other stakeholders in the cancer community to make submissions in support of the PBS listing.